Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia. - Wikidata - awgldk - TriplyDB

Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.

Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q37928299

about

Novel agents in mantle cell lymphoma Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells.New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come.Emerging immunopharmacological targets in multiple sclerosis.Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.Design and evaluation of radiolabeled tracers for tumor imaging.Protein engineering to target complement evasion in cancer.Mechanistic considerations for the use of monoclonal antibodies for cancer therapy.Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France.

P2860

Q27011763-C69374D1-4744-4702-B1C8-EBFE2B7B3DF5 Q35876847-F2C53334-F527-4AC2-9784-DBFBB5D88E86 Q36748702-58091800-DBC5-4BC5-BAA0-29A73024D465 Q37559970-B97ABF36-CDF3-4B27-B9AF-9782392EB440 Q38029382-2ACCFA49-C95F-442D-BC3D-2710B91F626A Q38137253-3EF1EDEC-650D-4482-AF21-837A30307E6B Q38163242-60FF275F-4F11-47B6-93E7-3F4367C4354E Q38204975-B428FAE3-2CCA-4819-B841-154171ACB220 Q38601727-45B1ABEB-522D-454A-A8F8-690AA06943B2 Q39117341-263F86B8-AEBA-462F-9CB1-6D000D97FB9B Q42333450-2F297A3A-C242-4F33-9960-725533C018CB

P2860

Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q37928299

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Ofatumumab: a novel anti-CD20 ...... chronic lymphocytic leukemia.

@en

Ofatumumab: a novel anti-CD20 ...... chronic lymphocytic leukemia.

@nl

type

label

Ofatumumab: a novel anti-CD20 ...... chronic lymphocytic leukemia.

@en

Ofatumumab: a novel anti-CD20 ...... chronic lymphocytic leukemia.

@nl

prefLabel

Ofatumumab: a novel anti-CD20 ...... chronic lymphocytic leukemia.

@en

Ofatumumab: a novel anti-CD20 ...... chronic lymphocytic leukemia.

@nl

P1433

Q37928299-36D95728-1E21-4559-BE24-8C6A43E809CD

P1476

Q37928299-21D0E4A6-32FC-4821-A741-62557ABB523C

P2093

Q37928299-BC4B295A-8FE1-4DC4-BBDA-D9A64AC79FBB

P2860

Q37928299-145B1B4B-DB38-44BA-A965-01EAD1B55E2B

Q37928299-1C1244F0-B713-4C22-AC92-A4CF24A2C8CB

Q37928299-2FF0A282-50D2-4F26-B809-B95BA6F3A452

Q37928299-32140CDC-1B97-44B9-8EAC-4657BBF5EF0D

Q37928299-36B5BF20-F782-4C83-ADFF-61CA3E2F7FA4

Q37928299-42443987-F935-400F-8240-8ED4571C2F2C

Q37928299-593A072A-0E30-4B8F-8A86-C6B6E035A14F

Q37928299-6B759C76-D962-4CA6-8122-9EE30F5A6D9C

Q37928299-779255D8-9DC9-4A74-B502-EF7F786C08AB

Q37928299-A184A1F0-D65E-4920-8567-974760DF879D

P304

Q37928299-59D493DD-EBBE-490F-A29D-491589E9A874

P31

Q37928299-54065408-2225-4761-8AA6-E3E1ED9516E8

P356

Q37928299-846F00A6-DD3F-4E7C-80B5-15BA1A61D39E

P407

Q37928299-86CB267F-2A48-4ED1-901A-C8D7198C69E7

P433

Q37928299-6057D3C4-AFAA-4222-B5BB-C4F01EA95F8F

P478

Q37928299-24A848FA-A37B-415F-8910-3A52978FB077

P577

Q37928299-342D8AB1-B0FD-4870-BB06-AA0F1E24F48A

P698

Q37928299-94B18E48-F376-452F-B832-BA2F9E1758DF

P921

Q37928299-71EDA1E3-670E-466F-B1F9-BBE0C3EB5BDB

Q37928299-C631FCDA-1111-43CC-A5C9-1DD5F6FF72D6

Q37928299-E22E4D2A-FB3E-4E78-A5FD-311B283994F0

P356

P1433

Annals of Pharmacotherapy

P1476

Ofatumumab: a novel anti-CD20 ...... chronic lymphocytic leukemia.

@en

P2093

Ginah Nightingale

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody.

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports

Current approach to diagnosis and management of chronic lymphocytic leukemia.

P304

1248-1255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1P780

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21896924

http://www.w3.org/2001/XMLSchema#string

P921